日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study

抗CD19嵌合抗原受体T细胞疗法治疗复发或难治性费城染色体阳性B细胞急性淋巴细胞白血病：一项多中心回顾性研究

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-026-04755-6
Yu, Jinglei; Song, Fengmei; Zhang, Mingming; Zhao, Mingfeng; Sang, Wei; Jiang, Songfu; Wang, Lixin; Wang, Xingbing; Tu, Sanfang; Li, Yuhua; Huang, He; Hu, Yongxian; Wei, Guoqing
B细胞
T细胞
信号转导
白血病
T细胞
细胞生物学
CD19
免疫/内分泌
发表日期：2026
文献求助 收藏

Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies

基因编辑的异体CAR-T细胞：下一代癌症免疫疗法

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01745-8
Su, Jingchao; Zeng, Yifei; Song, Zhuojin; Liu, Yinglu; Ou, Kaixin; Wu, Yuhan; Huang, Minhong; Li, Yuhua; Tu, Sanfang
肿瘤
T细胞
肿瘤免疫
T细胞
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma

嵌合抗原受体T细胞疗法联合泽布替尼治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效和安全性

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003504
Wang, Langqi; Yue, Chunyan; Zhou, Xuan; Yang, Jilong; Jin, Bo; Wang, Bo; Huang, Minhong; Chen, Huifang; Zhou, Lijuan; Tu, Sanfang; Li, Yuhua
淋巴瘤
信号转导
B细胞
免疫/内分泌
细胞生物学
T细胞
T细胞
发表日期：2025
文献求助 收藏

Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia

新型 CD19 快速 CAR-T 细胞与 CD19 传统 CAR-T 细胞治疗复发/难治性 CD19 阳性 B 细胞急性淋巴细胞白血病的比较

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003479
Tan, Xu; Wang, Jishi; Chen, Shangjun; Liu, Li; Li, Yuhua; Tu, Sanfang; Yi, Hai; Zhou, Jian; Wang, Sanbin; Liu, Ligen; Ge, Jian; Hu, Yongxian; Wang, Xiaoqi; Wang, Lu; Chen, Guo; Yao, Han; Zhang, Cheng; Zhang, Xi
白血病
细胞生物学
T细胞
CD19
发表日期：2025
文献求助 收藏

Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma

中国专家就CAR-T细胞疗法治疗淋巴瘤的多学科团队综合病例管理达成共识

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003085
Tu, Sanfang; Li, Ping; Mei, Heng; Liu, Yang; Hu, Yongxian; Liu, Peng; Zou, Dehui; Niu, Ting; Xu, Kailin; Wang, Li; Yang, Jianmin; Zhao, Mingfeng; Huang, Xiaojun; Wang, Jianxiang; Hu, Yu; Zhao, Weili; Wu, Depei; Ma, Jun; Qian, Wenbin; Han, Weidong; Li, Yuhua; Liang, Aibin
T细胞
淋巴瘤
T细胞
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience

对接受伊达比星或柔红霉素诱导治疗的非早幼粒细胞性急性髓系白血病（AML）患者的临床观察包括标准治疗方案：一家三级医疗中心的经验

期刊:
影响因子:
doi:10.1186/s40360-025-00839-w
Xu, Jianhui; Song, Chaoyang; He, Yanjie; Huang, Rui; Tu, Sanfang
细胞生物学
白血病
粒细胞
发表日期：2025
文献求助 收藏

Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies

关于嵌合抗原受体（CAR）-T细胞疗法治疗血液系统恶性肿瘤引起的细胞因子释放综合征（CRS）期间皮质类固醇的给药时机、剂量和使用建议

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003379
Tu, Sanfang; Luo, Xiu; Mei, Heng; Hu, Yongxian; Liu, Yang; Li, Ping; Zou, Dehui; Niu, Ting; Xu, Kailin; Zhang, Xi; Qiu, Lugui; Gao, Lei; Gao, Guangxun; Zhang, Li; Feng, Yimei; Wang, Ying; Zhao, Mingfeng; Mi, Jianqing; Hou, Ming; Yang, Jianmin; Huang, He; Wang, Jianxiang; Hu, Yu; Zhao, Weili; Wu, Depei; Ma, Jun; Li, Yuhua; Qian, Wenbin; Huang, Xiaojun; Han, Weidong; Liang, Aibin
肿瘤
T细胞
肿瘤免疫
信号转导
T细胞
细胞生物学
免疫/内分泌
发表日期：2024
文献求助 收藏

Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study

基于遗传学和微小残留病灶的风险导向治疗可改善AML1-ETO阳性AML患者的预后，一项多中心前瞻性队列研究

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-023-00941-4
Xu, Dan; Yang, Ying; Yin, Zhao; Tu, Sanfang; Nie, Danian; Li, Yiqing; Huang, Zhenqian; Sun, Qixin; Huang, Changfen; Nie, Xiaqi; Yao, Zurong; Shi, Pengcheng; Zhang, Yu; Jiang, Xuejie; Liu, Qifa; Yu, Guopan
发表日期：2023
文献求助 收藏

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

2022年中国专家共识及抗CD19嵌合抗原受体T细胞疗法治疗B细胞非霍奇金淋巴瘤毒性临床管理指南

期刊:Cancer Biology & Medicine
影响因子:8.4
doi:10.20892/j.issn.2095-3941.2022.0585
Li, Ping; Liu, Yang; Liang, Yun; Bo, Jian; Gao, Sujun; Hu, Yongxian; Hu, Yu; Huang, He; Huang, Xiaojun; Jing, Hongmei; Ke, Xiaoyan; Li, Jianyong; Li, Yuhua; Liu, Qifa; Lu, Peihua; Mei, Heng; Niu, Ting; Song, Yongping; Song, Yuqin; Su, Liping; Tu, Sanfang; Wang, Jianxiang; Wu, Depei; Wang, Zhao; Xu, Kailin; Ying, Zhitao; Yang, Qingming; Zhang, Yajing; Shi, Fengxia; Zhang, Bin; Zhang, Huilai; Zhang, Xi; Zhao, Mingfeng; Zhao, Weili; Zhao, Xiangyu; Huang, Liang; Zhu, Jun; Qian, Wenbin; Han, Weidong; Liang, Aibin
B细胞
T细胞
信号转导
淋巴瘤
T细胞
细胞生物学
毒理研究
CD19
免疫/内分泌
发表日期：2023
文献求助 收藏

Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

索拉非尼维持治疗对接受异基因造血干细胞移植的FLT3-ITD AML患者EB病毒和巨细胞病毒感染的影响：一项随机临床试验的二次分析

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-022-02479-x
Xu, Xin; Fan, Zhiping; Wang, Yu; Huang, Fen; Xu, Yajing; Sun, Jing; Xu, Na; Deng, Lan; Li, Xudong; Liang, Xinquan; Luo, Xiaodan; Shi, Pengcheng; Liu, Hui; Chen, Yan; Tu, Sanfang; Huang, Xiaojun; Liu, Qifa; Xuan, Li
巨细胞病毒感染
细胞生物学
炎症/感染
FLT3
微生物学
干细胞
发育与干细胞
发表日期：2022
文献求助 收藏